| abstract |
The present invention provides a novel formulation that alleviates aggregation induced by agitation of immunogenic compositions (specifically, those having a polysaccharide-protein conjugate). In particular, the novel formulations comprise poloxamers in the molecular weight range from 1100 to 17,400, and poloxamers provide surfactants superior to those previously employed, including polysorbate 80. Significant advantage. In one embodiment, the invention provides a multivalent immunogen composition having 15 different polysaccharide-protein conjugates and poloxamers. Each conjugate is derived from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F or 33F) The resulting capsular polysaccharide is coupled to a carrier protein (preferably CRM197) to constitute. |